| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Molecularly targeted therapy to receptor tyrosine kinase (RTK) suppresses the progression and metastasis of cancer and leads to improvement in QOL of patients with cancer and prolongation of survival. However long-term administration of RTK targeted drugs causes the emergence of drug-resistant cancer cells. Therefore, a biomarker, which can be to measure for the resistance or the response state against the RTK targeted drugs in the cancer cells, has great clinical significance. In this study, we found potential protein -biomarker candidates reflecting the activation state of RTK signaling in the RTK targeted drug -resistant GIST cell line by proteome analysis.
|
